Search
Talazoparib
go.drugbank.com/drugs/DB11760ApprovedInvestigationalTalazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib wa...
Categories: P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic IndexTenapanor
go.drugbank.com/drugs/DB11761ApprovedInvestigationalTenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C). It was first designed and synthesized in 2012. As an inhibitor of the sodium/hydro...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigationalRenal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesNeratinib
go.drugbank.com/drugs/DB11828ApprovedInvestigationalNeratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib i...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsOsilodrostat
go.drugbank.com/drugs/DB11837ApprovedInvestigationalCushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsTasisulam
go.drugbank.com/drugs/DB11941InvestigationalTasisulam has been used in trials studying the treatment and basic science of Melanoma, Lymphoma, Solid Tumors, Breast Cancer, and Ovarian Cancer, among others.
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsDelafloxacin
go.drugbank.com/drugs/DB11943ApprovedInvestigationalDelafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, a...
Categories: Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP3A InducersLemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigational[L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesDuvelisib
go.drugbank.com/drugs/DB11952ApprovedInvestigationalDuvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative a...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAvatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigational[A33095] Thrombocytopenia is a common complication in patients suffering from chronic liver disease, occurring as a result of liver disease or a consequence of interferon-based antiviral therapy.
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates